menu
    • menu
    [{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"PAKISTAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"PAKISTAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Dimension Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Peginterferon Alfa-2a","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Dimension Research","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Dimension Research"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"PAKISTAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ertugliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"PAKISTAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Febuxostat","moa":"Xanthine dehydrogenase","graph1":"Rheumatology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Rawalpindi Medical College, Pakistan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"PAKISTAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Acotiamide","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Rawalpindi Medical College, Pakistan","highestDevelopmentStatusID":"10","companyTruncated":"Getz Pharma \/ Rawalpindi Medical College, Pakistan"}]

    Find Clinical Drug Pipeline Developments & Deals by Getz Pharma

    Menu

    Getz Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acotiamide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Rawalpindi Medical College, Pakistan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Acotiamide vs Itopride in Postprandial Distress Syndrome

                            Details : Acotiamide is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dyspepsia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 15, 2025

                            Lead Product(s) : Acotiamide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Rawalpindi Medical College, Pakistan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tamsulosin

                            Therapeutic Area : Urology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi

                            Details : Tamsulosin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ureteral Calculi.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 04, 2023

                            Lead Product(s) : Tamsulosin

                            Therapeutic Area : Urology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ertugliflozin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFL...

                            Details : Ertugliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fatty Liver.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 09, 2022

                            Lead Product(s) : Ertugliflozin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

                            Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 03, 2022

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metformin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Pat...

                            Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 22, 2021

                            Lead Product(s) : Metformin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Stu...

                            Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 20, 2021

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

                            Details : Insulin is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            December 17, 2021

                            Lead Product(s) : Insulin

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pioglitazone

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty...

                            Details : Pioglitazone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2021

                            Lead Product(s) : Pioglitazone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

                            Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peginterferon Alfa-2a

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Dimension Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population

                            Details : Peginterferon Alfa-2a is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 11, 2015

                            Lead Product(s) : Peginterferon Alfa-2a

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Dimension Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth